Washington, DC (May 22, 2013)—
Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research at the Food and Drug Administration (FDA), yesterday delivered the keynote address at the Ninth Annual State of Personalized Medicine Luncheon hosted by the Personalized Medicine Coalition (PMC) at the National Press Club.
"With two new important personalized medicine announcements just last week which will improve clinical care for cancer patients, Dr. Woodcock's address comes at an opportune time," said Edward Abrahams, President, PMC.
Attended by over 150 innovators, patients, scientists, and government officials devoted to the understanding and adoption of personalized medicine, Dr. Woodcock discussed how the FDA is dealing with the expanding field of personalized medicine, including its efforts to encourage its development.
"Personalized medicine has moved from a goal to an emerging reality. The PMC has helped drive this transition. Many of the new 'breakthrough therapy' designations have involved targeted approaches. The new challenge will be to assist the larger health care community in dealing with this medical and scientific transition," stated Dr. Woodcock.
Stephen Eck, M.D, Head of Clinical Oncology, Astellas, stated while introducing Dr. Woodcock, "For those of us who are proponents of personalized medicine, this brings new responsibility: The responsibility of educating academic, industry, patient, provider and payer communities about the value of molecular diagnostics and the proper choice of medicines, an essential component of our personalized medicine future. Astellas is pleased to sponsor this luncheon."
The Personalized Medicine Coalition's annual "State of Personalized Medicine Luncheon" serves as a forum for PMC members and guests from across the health care community to engage with leaders in policy and to discuss key issues facing personalized medicine.
Previous keynote speakers at the State of Personalized Medicine Luncheon include Mark Levin, Partner and Co-Founder of Third Rock Ventures; John Castellani, President and CEO of PhRMA; Margaret Hamburg, M.D., Commissioner of the Food and Drug Administration; Denis Cortese, M.D., President and CEO of the Mayo Clinic; Harvey Fineberg, M.D., President of the Institute of Medicine; The Honorable Michael O. Leavitt, Secretary of Health and Human Services; Andrew von Eschenbach, M.D., Commissioner of the Food and Drug Administration; and Francis Collins, M.D., Ph.D., Director of the National Human Genome Research Institute.
About the Personalized Medicine Coalition:
The Personalized Medicine Coalition (PMC), representing innovators, scientists, patients, providers and payers, promotes the understanding and adoption of personalized medicine concepts, services and products to benefit patients and the health system. For more information about PMC, visit www.personalizedmedicinecoalition.org.